On July 8, Zai Lab rose 5.09% in regular trading, trading at HK$15.56/share, with turnover of HK$56.99 million. The stock outperformed the broader biotechnology sector as innovative drug names rallied.

On the news front, the sector is benefiting from continued positive policy signals following the National Healthcare Security Administration's publication of drugs passing the preliminary review for the basic medical insurance catalog and commercial insurance innovative drug catalog adjustment. Brokerages have highlighted that the adjustment mechanism demonstrates sustained policy support for innovative drugs, with the newly introduced pre-filing mechanism further favoring novel therapeutics. Separately, research notes point to Chinese innovative drug BD transaction values exceeding expectations, with the industry entering an intensive data catalyst period.

Within the Biotechnology sector, AKESO rose 3.43%, REMEGEN rose 3.85%, INNOVENT BIO rose 2.29%, BEIGENE rose 1.36%, while SKB BIO fell 5.14%. Zai Lab's outperformance relative to peers may also reflect its recent pipeline progress, including Zoci receiving both FDA fast track and EMA orphan drug designations, and the China approval of Tivdak for cervical cancer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)